Shots:

• Daiichi Sankyo to conduct two-part P-I study assessing U3-1402+ Tagrisso as both a 1L and 2L dual regimen in patients with advanced or mNSCLC with an EGFR exon 19 deletion or L858R mutation
• The dose-escalation part will assess the safety & tolerability of different dosing combinations of dual regimen to determine the recommended dose while the second part of the study (dose expansion) will include a 1L and 2L cohort to further evaluate the anti-tumor activity and safety of the regimen
• In the 1L cohort- patients will receive dual regimens and patients in the 2L cohort will be randomized in a ratio (1:1) to receive treatment with U3-1402 as monothx. or in combination with Tagrisso. 258 patients will be enrolled in the study- which will be conducted in NA- EU- and Asia including Japan

 Ref: Daiichi Sankyo  | Image: StraitTimes